Long-term antiarrhythmic therapy with cibenzoline

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This single-blind, placebo-controlled study evaluated long-term therapy with cibenzoline in 19 patients with chronic ventricular arrhythmias. Antiarrhythmic efficacy, defined as ≥75% reduction in single premature ventricular complexes (PVCs), ≥90% reduction in paired PVCs, and total abolition of ventricular tachycardia (VT), was established after dose titration in 14 of 19 (74%) patients. Mean frequency of single PVCs was reduced by 65%, mean paired PVC frequency was reduced by 68%, and mean VT event frequency was reduced by 82%. Antiarrhythmic efficacy was maintained during long-term therapy in five of the 14 (36%) short-term responders. Of the nine patients who discontinued cibenzoline during long-term follow-up, five had a loss of arrhythmia control, three failed to redevelop arrhythmias during placebo reintroduction, and one developed an adverse reaction. Three patients (16%) experienced a proarrhythmic effect. Echocardiographic evaluation did not reveal any deleterious effect of cibenzoline on left ventricular function in the group as a whole. In six patients with preexisting left ventricular dysfunction, left ventricular ejection fraction and fractional shortening improved significantly (P

Original languageEnglish
Pages (from-to)400-406
Number of pages7
JournalJournal of Clinical Pharmacology
Volume27
Issue number5
StatePublished - 1987

Fingerprint

Ventricular Premature Complexes
Cardiac Arrhythmias
Ventricular Tachycardia
Placebos
Therapeutics
Left Ventricular Dysfunction
Left Ventricular Function
Stroke Volume
cifenline

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Long-term antiarrhythmic therapy with cibenzoline. / Mohiuddin, Syed M.; Hilleman, Daniel E.; Esterbrooks, Dennis J.; Mooss, Aryan N.; Stengel, L. A.

In: Journal of Clinical Pharmacology, Vol. 27, No. 5, 1987, p. 400-406.

Research output: Contribution to journalArticle

@article{ab9edec1a8314388bb06d39f2a11157d,
title = "Long-term antiarrhythmic therapy with cibenzoline",
abstract = "This single-blind, placebo-controlled study evaluated long-term therapy with cibenzoline in 19 patients with chronic ventricular arrhythmias. Antiarrhythmic efficacy, defined as ≥75{\%} reduction in single premature ventricular complexes (PVCs), ≥90{\%} reduction in paired PVCs, and total abolition of ventricular tachycardia (VT), was established after dose titration in 14 of 19 (74{\%}) patients. Mean frequency of single PVCs was reduced by 65{\%}, mean paired PVC frequency was reduced by 68{\%}, and mean VT event frequency was reduced by 82{\%}. Antiarrhythmic efficacy was maintained during long-term therapy in five of the 14 (36{\%}) short-term responders. Of the nine patients who discontinued cibenzoline during long-term follow-up, five had a loss of arrhythmia control, three failed to redevelop arrhythmias during placebo reintroduction, and one developed an adverse reaction. Three patients (16{\%}) experienced a proarrhythmic effect. Echocardiographic evaluation did not reveal any deleterious effect of cibenzoline on left ventricular function in the group as a whole. In six patients with preexisting left ventricular dysfunction, left ventricular ejection fraction and fractional shortening improved significantly (P",
author = "Mohiuddin, {Syed M.} and Hilleman, {Daniel E.} and Esterbrooks, {Dennis J.} and Mooss, {Aryan N.} and Stengel, {L. A.}",
year = "1987",
language = "English",
volume = "27",
pages = "400--406",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Long-term antiarrhythmic therapy with cibenzoline

AU - Mohiuddin, Syed M.

AU - Hilleman, Daniel E.

AU - Esterbrooks, Dennis J.

AU - Mooss, Aryan N.

AU - Stengel, L. A.

PY - 1987

Y1 - 1987

N2 - This single-blind, placebo-controlled study evaluated long-term therapy with cibenzoline in 19 patients with chronic ventricular arrhythmias. Antiarrhythmic efficacy, defined as ≥75% reduction in single premature ventricular complexes (PVCs), ≥90% reduction in paired PVCs, and total abolition of ventricular tachycardia (VT), was established after dose titration in 14 of 19 (74%) patients. Mean frequency of single PVCs was reduced by 65%, mean paired PVC frequency was reduced by 68%, and mean VT event frequency was reduced by 82%. Antiarrhythmic efficacy was maintained during long-term therapy in five of the 14 (36%) short-term responders. Of the nine patients who discontinued cibenzoline during long-term follow-up, five had a loss of arrhythmia control, three failed to redevelop arrhythmias during placebo reintroduction, and one developed an adverse reaction. Three patients (16%) experienced a proarrhythmic effect. Echocardiographic evaluation did not reveal any deleterious effect of cibenzoline on left ventricular function in the group as a whole. In six patients with preexisting left ventricular dysfunction, left ventricular ejection fraction and fractional shortening improved significantly (P

AB - This single-blind, placebo-controlled study evaluated long-term therapy with cibenzoline in 19 patients with chronic ventricular arrhythmias. Antiarrhythmic efficacy, defined as ≥75% reduction in single premature ventricular complexes (PVCs), ≥90% reduction in paired PVCs, and total abolition of ventricular tachycardia (VT), was established after dose titration in 14 of 19 (74%) patients. Mean frequency of single PVCs was reduced by 65%, mean paired PVC frequency was reduced by 68%, and mean VT event frequency was reduced by 82%. Antiarrhythmic efficacy was maintained during long-term therapy in five of the 14 (36%) short-term responders. Of the nine patients who discontinued cibenzoline during long-term follow-up, five had a loss of arrhythmia control, three failed to redevelop arrhythmias during placebo reintroduction, and one developed an adverse reaction. Three patients (16%) experienced a proarrhythmic effect. Echocardiographic evaluation did not reveal any deleterious effect of cibenzoline on left ventricular function in the group as a whole. In six patients with preexisting left ventricular dysfunction, left ventricular ejection fraction and fractional shortening improved significantly (P

UR - http://www.scopus.com/inward/record.url?scp=0023605508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023605508&partnerID=8YFLogxK

M3 - Article

C2 - 3693585

AN - SCOPUS:0023605508

VL - 27

SP - 400

EP - 406

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 5

ER -